My Hbv story for gew years

[TaG_99]

These are my 2,7 years adventure with Entecavir+Tenofovir...

I guess I have to take medication for as log as I'm alive?

Any hints would be most welcome..

Thanks

[TaG_99]

I found out about HbV back in 2006.
AND
did not pay any attention to it as some stupid doctor said "you have already cleared the infection"... Accordingly for over 10 years I was eating, drinking (lot of beer:)) and only become alert in 2013 (when I started the treatment).

So, please do not consider my case as indicative, as I was (intentionally or not) doing everything to make the disease progress even worse. Even during period of 2013-2015 I was occasionally drinking a bit of beer, whiskey, etc. Now I'm totally cancelled the beverage, but it may be too late for effective reversal to close to normal conditions.

[stef2011]

just follow all my older posts and see how i got from 16.3kpa to around 6kpa by 2 years, not saying anybody can clear fibrosis so fast but definitely possible by antivirals, vitamins/antioxidants, life style food quality, gcmaf, vit d3 and so on

definitely check it all because after 5 years i also cleared all nodules which is not reported as possible on scientific articles.pisa researchers told me they had one case similar to mine but their patient cured hbv by antivirals/pegintf combo and took him more than 10 years to clear nodules

[TaG_99]

Well as shown in the picture my median fibroscan is around 23. Which is almost getting to decompensated cirrhosis, although I "enjoy" this condition for about two years now without any progress...

[melcul]

Hy, sorry to ask, but when you discovered that you are hbv positive did you already had cirrhosis ? do you know how long have you had it ?

[TaG_99]

THANKS !

[StephenCastlecrag]

See the following article for some latest information on stopping antivirals. Taiwan doctors are in favor of stopping, but not the European doctors. So don't stop without consulting your doctor.
In my opinion, you should do a fibroscan to ascertain the state of your liver before even considering stopping to confirm that your cirrhosis has regressed.


Lasting virological remission post-discontinuation of HBV therapy may be possible

Papatheodoridis G, et al. Hepatology. 2016;doi:10.1002/hep.28438.
March 8, 2016

  
In a systematic review, researchers found that patients who discontinued long-term nucleos(t)ide analogue therapy for chronic hepatitis B virus infection were still capable of maintaining virological remission, according to published findings.


“The need for long-term [nucleos(t)ide analogue] therapy raises safety issues for some patients … and family planning issues in patients of reproductive age along with increases in treatment costs. Many physicians treating [patients with chronic HBV] with [nucleos(t)ide analogue] for years have become interested in investigating the need for continuation as well as the safety of therapy withdrawal. … Limitation of long-term duration of [nucleos(t)ide analogue] therapy seems to be one of the major aims nowadays,” George Papatheodoridis, MD, director, department of gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital of Athens, Greece, and colleagues wrote.

George Papatheodoridis, MD



Researchers analyzed data of 1,716 patients with chronic HBV from 25 studies from 2002 to 2014, who discontinued nucleos(t)ide analogue (NA) treatment. The goal was to determine factors that affect the probability of post-treatment remission, according to the research.

Overall, pooled rates of lasting virological remission were 51.4% at 1 year, 39.3% at 2 years and 38.2% at 3 years after NA discontinuation. These rates were higher in patients initially positive for hepatitis B e antigen (HBeAg; 62.5%, 53.4%, 51.5%) compared with patients who were HBeAg-negative (43.7%, 31.3%, 30.1%; P = .064).

The weighted probability of lasting biochemical HBV remission was 65.4%. This was also higher in patients who were HBeAg-positive (76.2%) compared with patients who were HBeAg-negative (56.7%, P = .13).

The weighted probability of lasting HBeAg seroconversion was 91.9% at 1 year and 88% at 2 years after NA discontinuation. This was not affected by the duration of on-therapy virological remission or consolidation therapy, which was greater than 6 months in all of the studies.

The weighted probability of hepatitis B surface antigen loss was 2%.

The rates of lasting virological remission were not different based on varying definitions of virological remission or duration of on-therapy virological remission in patients who were HBeAg-positive. However, the rate of virological remission 1 year after NA discontinuation was 75% in studies that had on-therapy virological remission durations of greater than 2 years and 35.6% in studies that had on-therapy virological remission durations of less than 2 years (P = .005).

The researchers concluded: “Discontinuation of long-term NA therapy may be attempted if close follow-up can be guaranteed in patients without advanced liver disease.” – by Melinda Stevens

Disclosure: Papatheodoridis reports consulting, advising and speaking for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, MSD and Roche; has received grants from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Roche; and is an advisor and speaker for Novartis. Please see the full study for a list of all other authors’ relevant financial disclosures.

[TaG_99]

Sorry,

Forgot some details.

Age: 56
All measurements are standard units, i.e. HBsAg ie/ml, etc.

So far compensates cirrhosis